BioCentury | Oct 9, 2020
Emerging Company Profile
A2: targeting lost genetic material to distinguish tumors from normal cells
...$136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments...
